Author's response to reviews

Title: The Procalcitonin And Survival Study (PASS) - A Randomised multi-center trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

Authors:

Jens-Ulrik Jensen (koordinator@pass-studiet.dk)
Bettina E Lundgren (bettina.lundgren@hvh.regionh.dk)
Lars Hein (larshein@post5.tele.dk)
Thomas Mohr (t.mohr@dudadlnet.dk)
Pernille L Petersen (pernelle.lykke.petersen@dadalnet.dk)
Lasse H Andersen (lasse.andersen@dadalnet.dk)
Anne Ø Lauritsen (annelauritsen@dadalnet.dk)
Sine Hougaard (thomassine@hotmail.com)
Teit Mantoni (temantoni@hotmail.com)
Bonnie Bømler (bon_bom@hotmail.com)
Klaus J Thornberg (klaust@dadalnet.dk)
Katrin Thormar (kata@tdcadsl.dk)
Jesper Løken (jesper.loeken@hvh.regionh.dk)
Morten Steensen (morten.steensen@hvh.regionh.dk)
Peder Carl (peder.carl@hvh.regionh.dk)
J. Asger Petersen (john.asger.petersen@hvh.regionh.dk)
Hamid Tousi (hamid.tousi@yahoo.com)
Peter Søe-Jensen (pesj@heh.regionh.dk)
Morten MB Bestle (mbes@hih.regionh.dk)
Søren Hestad (s.hestad@dadalnet.dk)
Mads H Andersen (mha@dadalnet.dk)
Paul Fjeldborg (pfb@sks.aaa.dk)
Kim M Larsen (kml@dadalnet.dk)
Charlotte D CDR Rossau (cdr@dadalnet.dk)
Carsten B Thomsen (cbth@mail.dk)
Christian Østergaard (coa@ssi.dk)
Jesper K Kjær (ikj@cphiv.dk)
Jesper Grarup (jgr@cphiv.dk)
Jens D Lundgren (jdl@cphiv.dk)

Version: 3 Date: 3 July 2008

Author's response to reviews:

Dear Editor,

We have removed website addresses from the manuscript and moved them to the reference list.
Table 1 is now cited in the text

We have corrected the details on the authors list. The title page has been regarding recruitment start and study registration. Section headings have been changed to apply for journal format. The additional file (table) has been removed, since it is already embedded in the main text body. Fig. 1 is now referred to as Figure 1.

Best regards,

Jens-Ulrik Jensen, MD, Project Coordinator